3-Deoxysappanchalcone

Name: 3-Deoxysappanchalcone
Brand: MedChemExpress
SKU: HY-N1745A
Rating: 5.0 (2 reviews)

Cat. No.: HY-N1745A Purity: 99.77%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

3-Deoxysappanchalcone is a kinase inhibitor and antiviral agent. 3-Deoxysappanchalcone directly targets MET, EGFR, AKT, mTOR, p38 MAPK, JNK, thrombin, FXa, and influenza virus neuraminidase, thereby regulating related signaling pathways. 3-Deoxysappanchalcone induces cell cycle arrest, ROS production, and apoptosis. 3-Deoxysappanchalcone exhibits anti-inflammatory, anti-allergic, anticoagulant, and antithrombotic activities. 3-Deoxysappanchalcone is applicable to research related to gefitinib-resistant lung cancer, esophageal squamous cell carcinoma, thrombosis, and influenza virus infection.

For research use only. We do not sell to patients.

3-Deoxysappanchalcone Chemical Structure

CAS No. : 112408-67-0

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Other Forms of 3-Deoxysappanchalcone:

2'-O-Methylisoliquiritigenin In-stock

2 Publications Citing Use of MCE 3-Deoxysappanchalcone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 1.06 μM (H3N2)^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
3T3-L1	IC₅₀	41.8 μM Compound: 6	Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining	[PMID: 19757853]
A549	IC₅₀	32.6 μM Compound: 11	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 21800859]
A549	IC₅₀	62.1 μM Compound: 29	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18440233]
A549	IC₅₀	66.5 μM Compound: 26	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 19689125]
B16-BL6	IC₅₀	49.9 μM Compound: 26	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 19689125]
B16-BL6	IC₅₀	56.3 μM Compound: 29	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 18440233]
Ca9-22	IC₅₀	57.56 μM Compound: 11	Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay Cytotoxicity against human Ca9-22 cells after 3 days by MTT assay	[PMID: 21800859]
HT-1080	IC₅₀	26.7 μM Compound: 26	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 19689125]
HT-1080	IC₅₀	51.2 μM Compound: 29	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 18440233]
HeLa	IC₅₀	33.3 μM Compound: 26	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 19689125]
HeLa	IC₅₀	67.9 μM Compound: 29	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18440233]
Hep 3B2	IC₅₀	17.89 μM Compound: 11	Cytotoxicity against human Hep3B cells after 3 days by MTT assay Cytotoxicity against human Hep3B cells after 3 days by MTT assay	[PMID: 21800859]
HepG2	IC₅₀	7.37 μM Compound: 11	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 21800859]
MCF7	IC₅₀	51.41 μM Compound: 11	Cytotoxicity against human MCF7 cells after 3 days by MTT assay Cytotoxicity against human MCF7 cells after 3 days by MTT assay	[PMID: 21800859]
MDA-MB-231	IC₅₀	44.44 μM Compound: 11	Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay	[PMID: 21800859]
RAW264.7	IC₅₀	8.1 μM Compound: 13	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 23127886]

In Vitro

3-Deoxysappanchalcone (12 h) directly binds to EGFR and MET proteins in HCC827GR gefitinib-resistant human lung adenocarcinoma cells^[1].
3-Deoxysappanchalcone (3-12 μM; 1 h) inhibits purified EGFR kinase activity with dose-dependent efficacy^[1].
3-Deoxysappanchalcone (3-12 μM; 24-48 h) reduces HCC827GR gefitinib-resistant human lung adenocarcinoma cell viability in a dose- and time-dependent manne^[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) induces apoptotic cell death in HCC827GR gefitinib-resistant human lung adenocarcinoma cells in a dose-dependent manner^[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) induces G₂/M cell cycle arrest and increases apoptotic sub-G₁ cell population in HCC827GR gefitinib-resistant human lung adenocarcinoma cells^[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) inhibits phosphorylation of EGFR, MET, AKT, and ERK in HCC827GR gefitinib-resistant human lung adenocarcinoma cells, reducing p-EGFR to 0.31-fold and p-MET to 0.24-fold of control at 12 μM after 48 h^[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) increases intracellular ROS levels and induces ER stress in HCC827GR gefitinib-resistant human lung adenocarcinoma cells, and ROS scavenger NAC abrogates 3-DSC-induced cell death^[1].
3-Deoxysappanchalcone (6-12 μM; 48 h) induces mitochondrial depolarization and intrinsic mitochondrial apoptosis in HCC827GR gefitinib-resistant human lung adenocarcinoma cells, and modulating Bcl-2 family proteins and cytochrome C translocation^[1].
3-Deoxysappanchalcone (3-DSC) (5-20 μM; 48 h) induces concentration-dependent multi-caspase activation and upregulation of cleaved caspase-3 and cleaved caspase-7 expression in KYSE 30 and KYSE 410 ESCC cells, and this caspase activation is reversed by pretreatment with the ROS scavenger NAC (6 mM; 3 h prior to 3-DSC treatment)^[3].
3-Deoxysappanchalcone (1-20 μM; 1 min) significantly prolongs aPTT and PT in human plasma at concentrations of 5 μM and higher, with concentrations of 18.7 μM and 17.3 μM required to double aPTT and PT, respectively^[4].
3-Deoxysappanchalcone (2-20 μM; 20 min) dose-dependently reduces the maximum rate of thrombin-catalyzed fibrin polymerization in human plasma at concentrations of 2, 3, 5, 10, and 20 μM^[4].
3-Deoxysappanchalcone (5-50 μM; 48 h) exhibits no cytotoxicity in HUVECs at concentrations up to 50 μM following 48 h of incubation^[4].
3-Deoxysappanchalcone (0.001-10 μM; 1 min) dose-dependently inhibits the amidolytic activity of thrombin in a cell-free system at concentrations of 0.001, 0.01, 0.1, 1, and 10 μM, with significant inhibition at 1 μM and higher^[4].
3-Deoxysappanchalcone (0.001-10 μM; 1 min) dose-dependently inhibits the amidolytic activity of FXa in a cell-free system at concentrations of 0.001, 0.01, 0.1, 1, and 10 μM, with significant inhibition at 1 μM and higher^[4].
3-Deoxysappanchalcone (1-20 μM; 10 min preincubation) dose-dependently inhibits thrombin production from prothrombin in HUVECs at concentrations of 1, 2, 3, 5, 10, and 20 μM following a 10 min preincubation^[4].
3-Deoxysappanchalcone (1-20 μM; 10 min preincubation) dose-dependently inhibits TNF-α-stimulated FXa production in HUVECs at concentrations of 1, 2, 3, 5, 10, and 20 μM following a 10 min preincubation^[4].
3-Deoxysappanchalcone (2-20 μM; 18 h) dose-dependently suppresses TNF-α-stimulated PAI-1 secretion in HUVECs at concentrations of 2, 3, 5, 10, and 20 μM over 18 h, mitigating the TNF-α-induced increase in the PAI-1/t-PA ratio without significantly affecting t-PA secretion^[4].
3-Deoxysappanchalcone inhibits influenza virus A/PR/8/34 (H1N1) NA with an IC₅₀ of 14.6 μg/mL^[5].
3-Deoxysappanchalcone inhibits influenza virus A/Guangdong/243/72 (H3N2) NA with an IC₅₀ of 17.4 μg/mL^[5].
3-Deoxysappanchalcone inhibits influenza virus B/Jiangsu/10/2003 NA with an IC₅₀ of 18.6 μg/mL^[5].
3-Deoxysappanchalcone inhibits influenza virus A/Guangdong/243/72 (H3N2)-induced cytopathic effects in MDCK cells with an IC₅₀ of 1.06 μg/mL, a CC₅₀ of 17.25 μg/mL, and a selective index of 16.27^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	HCC827GR gefitinib-resistant human lung adenocarcinoma cells
Concentration:	3-12 μM (24 h incubation); 3-12 μM (48 h incubation)
Incubation Time:	24 h; 48 h
Result:	Reduced HCC827GR cell viability in a dose- and time-dependent manner.

Apoptosis Analysis^[1]

Cell Line:	HCC827GR gefitinib-resistant human lung adenocarcinoma cells
Concentration:	6-12 μM
Incubation Time:	48 h
Result:	Induced apoptotic cell death in a dose-dependent manner.

Cell Cycle Analysis^[1]

Cell Line:	HCC827GR gefitinib-resistant human lung adenocarcinoma cells
Concentration:	6-12 μM
Incubation Time:	48 h
Result:	Increased the sub-G1 (apoptotic) cell population and induced G2/M cell cycle arrest.

Western Blot Analysis^[1]

Cell Line:	HCC827GR gefitinib-resistant human lung adenocarcinoma cells
Concentration:	6-12 μM
Incubation Time:	48 h
Result:	Reduced phosphorylation of EGFR (Tyr1068) to 0.88-, 0.76-, and 0.31-fold of control at 6, 9, and 12 μM, respectively, without altering total EGFR protein levels. Reduced phosphorylation of MET (Tyr1234/1235) to 0.94-, 0.27-, and 0.24-fold of control at 6, 9, and 12 μM, respectively, without altering total MET protein levels. Reduced phosphorylation of downstream AKT (Ser473) to 0.72-, 0.39-, and 0.32-fold of control, and phosphorylation of ERK (Thr202/Tyr204) to 0.88-, 0.85-, and 0.68-fold of control at 6, 9, and 12 μM, respectively, without altering total AKT or ERK protein levels.

ELISA Assay^[4]

Cell Line:	Human umbilical vein endothelial cells (HUVECs)
Concentration:	2-20 μM
Incubation Time:	18 h (with TNF-α)
Result:	Markedly suppressed TNF-α-stimulated PAI-1 release in a concentration-dependent fashion, with significant inhibition observed from 5 μM onward. Did not significantly affect t-PA secretion from HUVECs. Mitigated the TNF-α-induced increase in the PAI-1/t-PA ratio.

In Vivo

3-Deoxysappanchalcone (3-DSC) (50 mg/kg; i.p.; single dose 1 hour prior to LPS challenge) provides 100% survival protection against LPS-induced lethal systemic inflammation in male C57BL/6 mice^[2].
3-Deoxysappanchalcone (0.02-0.4 mg/kg; i.v.) significantly prolongs tail bleeding time in male C57BL/6 mice at doses of 0.1 mg/kg, 0.2 mg/kg, and 0.4 mg/kg, with the highest tested dose (0.4 mg/kg) extending bleeding time to 82.3 s^[4].
3-Deoxysappanchalcone (0.02-0.4 mg/kg; i.v.) significantly prolongs ex vivo aPTT and PT in male C57BL/6 mice at doses of 0.1 mg/kg, 0.2 mg/kg, and 0.4 mg/kg, with the highest tested dose (0.4 mg/kg) increasing aPTT to 47.9 ± 0.8 s and PT to 29.4 ± 1.2 s^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 (male, 20-22 g, LPS-induced systemic inflammation)^[2]
Dosage:	50 mg/kg
Administration:	i.p.; single dose (1 hour prior to LPS challenge)
Result:	Achieved 100% survival rate over 6 days.

Animal Model:	C57BL/6 (male, 6-7 weeks old, 27 g)^[4]
Dosage:	0.02 mg/kg; 0.04 mg/kg; 0.06 mg/kg; 0.1 mg/kg; 0.2 mg/kg; 0.4 mg/kg
Administration:	i.v.
Result:	Prolonged tail bleeding time to 48.1 s at 0.1 mg/kg, 63.1 s at 0.2 mg/kg, and 82.3 s at 0.4 mg/kg. Prolonged ex vivo aPTT to 35.4 s and PT to 23.8 s at 0.1 mg/kg, aPTT to 38.5 s and PT to 28.7 s at 0.2 mg/kg, and aPTT to 47.9 s and PT to 29.4 s at 0.4 mg/kg.

Molecular Weight

270.28

Formula

C₁₆H₁₄O₄

CAS No.

112408-67-0

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(/C=C/C1=CC=C(C=C1)O)C2=CC=C(C=C2OC)O

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (184.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.6999 mL	18.4993 mL	36.9987 mL
5 mM	0.7400 mL	3.6999 mL	7.3997 mL
10 mM	0.3700 mL	1.8499 mL	3.6999 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.77%

Select Batch:

Data Sheet (285 KB) SDS (252 KB)

COA (245 KB) HNMR (269 KB) RP-HPLC (295 KB)

Handling Instructions (2659 KB)

References

[1]. Lee JY, et al. 3-Deoxysappanchalcone Inhibits Cell Growth of Gefitinib-Resistant Lung Cancer Cells by Simultaneous Targeting of EGFR and MET Kinases. Biomol Ther (Seoul). 2023;31(4):446-455. [Content Brief]

[2]. Kim JH, et al. The anti-inflammatory effect of 3-deoxysappanchalcone is mediated by inducing heme oxygenase-1 via activating the AKT/mTOR pathway in murine macrophages. Int Immunopharmacol. 2014;22(2):420-426. [Content Brief]

[3]. Kwak AW, et al. The 3-deoxysappanchalcone induces ROS-mediated apoptosis and cell cycle arrest via JNK/p38 MAPKs signaling pathway in human esophageal cancer cells. Phytomedicine. 2021;86:153564. [Content Brief]

[4]. Han G, et al. Anti-Thrombotic Activity of 3-Deoxysappanchalcone via Inhibiting Platelet Aggregation and Thrombin (FIIa)/Activated Factor X (FXa) Activity. Molecules. 2025;30(12):2580. Published 2025 Jun 13. [Content Brief]

[5]. Liu AL, et al. In vitro anti-influenza viral activities of constituents from Caesalpinia sappan. Planta Med. 2009;75(4):337-339. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.6999 mL	18.4993 mL	36.9987 mL	92.4967 mL
	5 mM	0.7400 mL	3.6999 mL	7.3997 mL	18.4993 mL
	10 mM	0.3700 mL	1.8499 mL	3.6999 mL	9.2497 mL
	15 mM	0.2467 mL	1.2333 mL	2.4666 mL	6.1664 mL
	20 mM	0.1850 mL	0.9250 mL	1.8499 mL	4.6248 mL
	25 mM	0.1480 mL	0.7400 mL	1.4799 mL	3.6999 mL
	30 mM	0.1233 mL	0.6166 mL	1.2333 mL	3.0832 mL
	40 mM	0.0925 mL	0.4625 mL	0.9250 mL	2.3124 mL
	50 mM	0.0740 mL	0.3700 mL	0.7400 mL	1.8499 mL
	60 mM	0.0617 mL	0.3083 mL	0.6166 mL	1.5416 mL
	80 mM	0.0462 mL	0.2312 mL	0.4625 mL	1.1562 mL
	100 mM	0.0370 mL	0.1850 mL	0.3700 mL	0.9250 mL